Literature DB >> 36258730

Favorable HLA Polymorphisms are Associated with Lower Molecular Relapse after Tyrosine Kinase Discontinuation in Patients with Chronic Myeloid Leukemia.

Hiroshi Ureshino1, Kazuharu Kamachi1, Takero Shindo2, Shinya Kimura1.   

Abstract

Entities:  

Year:  2022        PMID： 36258730      PMCID： PMC9569246          DOI： 10.1007/s12288-022-01538-w

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.915


× No keyword cloud information.
  5 in total

Review 1.  Role of cancer immunology in chronic myelogenous leukemia.

Authors:  Hiroshi Ureshino; Takero Shindo; Shinya Kimura
Journal:  Leuk Res       Date:  2019-11-18       Impact factor: 3.156

2.  Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Authors:  Susanne Saussele; Johan Richter; Joelle Guilhot; Franz X Gruber; Henrik Hjorth-Hansen; Antonio Almeida; Jeroen J W M Janssen; Jiri Mayer; Perttu Koskenvesa; Panayiotis Panayiotidis; Ulla Olsson-Strömberg; Joaquin Martinez-Lopez; Philippe Rousselot; Hanne Vestergaard; Hans Ehrencrona; Veli Kairisto; Katerina Machová Poláková; Martin C Müller; Satu Mustjoki; Marc G Berger; Alice Fabarius; Wolf-Karsten Hofmann; Andreas Hochhaus; Markus Pfirrmann; Francois-Xavier Mahon
Journal:  Lancet Oncol       Date:  2018-05-04       Impact factor: 41.316

3.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

4.  Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.

Authors:  Shinya Kimura; Jun Imagawa; Kazunori Murai; Masayuki Hino; Toshio Kitawaki; Masaya Okada; Hideo Tanaka; Motohiro Shindo; Takashi Kumagai; Takayuki Ikezoe; Nobuhiko Uoshima; Tsutomu Sato; Reiko Watanabe; Shugo Kowata; Masaya Hayakawa; Takaaki Hosoki; Kazuhiko Ikeda; Tsutomu Kobayashi; Yasutaka Kakinoki; Tetsuo Nishimoto; Naoki Takezako; Hirohiko Shibayama; Akifumi Takaori-Kondo; Hirohisa Nakamae; Atsushi Kawaguchi; Hiroshi Ureshino; Junichi Sakamoto; Yoji Ishida
Journal:  Lancet Haematol       Date:  2020-01-21       Impact factor: 18.959

5.  HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Hiroshi Ureshino; Takero Shindo; Hidenori Tanaka; Hiroh Saji; Shinya Kimura
Journal:  Mol Cancer Ther       Date:  2020-10-20       Impact factor: 6.261
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.